Posts

Showing posts with the label Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) market outlook

Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Ovarian cancer is a type of malignancy that occurs in women. The majority of ovarian cancers, up to 90%, originate from the epithelial cells of the ovary. These cancers can be further classified into subtypes based on their histological and immunohistochemical characteristics, with the most common subtypes being high-grade serous (70%), low-grade serous, high-grade endometrioid, low-grade endometrioid, clear cell, and mucinous carcinomas. Low-grade serous carcinoma of the ovary or peritoneum (LGSC) is a rare subtype, accounting for between 5 and 8% of all ovarian carcinomas. LGSC can develop from a precursor lesion known as a serous borderline ovarian tumor (SBOT) or a de novo malignancy in the ovary or peritoneum. Patients with LGSC may present with non-specific symptoms such as abdominal discomfort, bloating, dyspnea, dyspepsia, and changes in bowel movement patterns. Alternatively, it may arise from the malignant transformation of a borderline ovarian tumor. LGSOC is charact...

Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Ovarian cancer is a type of malignancy that occurs in women. The majority of ovarian cancers, up to 90%, originate from the epithelial cells of the ovary. These cancers can be further classified into subtypes based on their histological and immunohistochemical characteristics, with the most common subtypes being high-grade serous (70%), low-grade serous, high-grade endometrioid, low-grade endometrioid, clear cell, and mucinous carcinomas. Low-grade serous carcinoma of the ovary or peritoneum (LGSC) is a rare subtype, accounting for between 5 and 8% of all ovarian carcinomas. LGSC can develop from a precursor lesion known as a serous borderline ovarian tumor (SBOT) or a de novo malignancy in the ovary or peritoneum. Patients with LGSC may present with non-specific symptoms such as abdominal discomfort, bloating, dyspnea, dyspepsia, and changes in bowel movement patterns. Alternatively, it may arise from the malignant transformation of a borderline ovarian tumor. LGSOC is characteri...

Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Ovarian cancer is a type of malignancy that occurs in women. The majority of ovarian cancers, up to 90%, originate from the epithelial cells of the ovary. These cancers can be further classified into subtypes based on their histological and immunohistochemical characteristics, with the most common subtypes being high-grade serous (70%), low-grade serous, high-grade endometrioid, low-grade endometrioid, clear cell, and mucinous carcinomas. Low-grade serous carcinoma of the ovary or peritoneum (LGSC) is a rare subtype, accounting for between 5 and 8% of all ovarian carcinomas. LGSC can develop from a precursor lesion known as a serous borderline ovarian tumor (SBOT) or a de novo malignancy in the ovary or peritoneum. Patients with LGSC may present with non-specific symptoms such as abdominal discomfort, bloating, dyspnea, dyspepsia, and changes in bowel movement patterns. Alternatively, it may arise from the malignant transformation of a borderline ovarian tumor. LGSOC is characteri...